# Scioto Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scioto-biosciences

- Industry: Biotechnology
- Headquarters: Indianapolis, US
- Website: www.sciotobiosciences.com
- Total disclosed funding: $1.8M
- Latest round: Series A (May 8, 2018)
- Investors on record: 3

## About

Scioto Biosciences, Inc. is a biotechnology firm focused on developing Activated Bacterial Therapeutics to address gastrointestinal disorders and conditions related to the central nervous system, especially autism spectrum disorder.Founded in 2017 and headquartered in Indianapolis, US, Scioto Biosciences, Inc. develops innovative therapies leveraging beneficial bacteria for gastrointestinal health. The company raised USD 26.5 mn in Series B funding on August 11, 2020, led by Genome & Company. Joseph Trebley serves as both CEO and Founder, bringing experience that guides the company's strategic direction.Scioto Biosciences, Inc. specializes in Activated Bacterial Therapeutics aimed at treating gastrointestinal disorders and conditions linked to the central nervous system, particularly autism spectrum disorder (ASD). Their primary product, SB-121, is an investigational probiotic designed to enhance beneficial bacteria's biofilm formation within the GI tract, targeting healthcare providers and research institutions seeking effective therapeutic options.Scioto Biosciences employs a revenue model based on partnerships with healthcare providers and research institutions utilizing their proprietary products in clinical environments. They also engage in direct-to-consumer sales, especially for SB-121, which is distributed via specialized medical channels and pharmacies. Pricing strategies are tailored to reflect the value of their therapeutic offerings, although specific pricing for SB-121 and other products remains undisclosed.Following their Series B funding of USD 26.5 mn in August 2020, Scioto Biosciences plans to leverage this capital to further develop their product pipeline, including upcoming launches of new therapies focused on gastrointestinal health. The company is targeting expansion into North American and European markets by mid-2023, aiming to meet the rising demand for effective interventions in ASD and GI disorders.

## Funding rounds

- Series A, May 8, 2018, $1.8M — BioCrossroads, Elevate Ventures, Rev1 Ventures

## Investors

- BioCrossroads (https://capitalatlas.ai/funds/biocrossroads) — Series A
- Elevate Ventures (https://capitalatlas.ai/funds/elevate-ventures) — Series A
- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Series A